<DOC>
	<DOCNO>NCT00625014</DOCNO>
	<brief_summary>We hypothesize short-term treatment haloperidol induces insulin resistance mechanistic route independent weight gain . We therefore treat healthy non-obese men haloperidol 8 day , studied impact intervention glucose lipid metabolism hyperinsulinemic euglycemic clamp , isotope dilution technology indirect calorimetry .</brief_summary>
	<brief_title>Metabolic Effects Subchronic Dopamine D2 Receptor Blockade Haloperidol Healthy Humans</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>Healthy men 20 kg/m2 &lt; BMI &lt; 26 kg/m2 Age 2040 year FPG &lt; 6 mmol/L FPG &gt; 6 mmol/L BMI &gt; 26 kg/m2 Psychiatric disorder and/or use antipsychotic antidepressant drug present past . A positive family history schizophrenia Any significant chronic disease Renal , hepatic endocrine disease Use medication know influence lipolysis and/or glucose metabolism Total cholesterol &gt; 7mmol/L and/or triglyceride &gt; 2 mmol/L Recent weight change attempt loose weight ( &gt; 3 kg weight gain loss , within last 3 month ) Difficulties insert intravenous catheter Smoking ( current ) Severe claustrophobia ( ventilate hood ) Recent blood donation ( within last 2 month ) Recent participation research project ( within last 3 month ) , participation 2 project one year Extensive sporting activity ( 10 hour exercise per week )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Insulin resistance</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Haloperidol</keyword>
</DOC>